文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症心肌病机制与治疗的研究进展

[Research advance of the mechanism and treatment of septic cardiomyopathy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论脓毒症心肌病表现为双心室扩张伴左心室射血分数下降,机制涉及线粒体功能障碍、心肌细胞凋亡和钙循环障碍,治疗包括常规治疗、β1受体阻滞剂和中医药。

脓毒症是机体对感染反应失调导致的危及生命的器官功能障碍,是创伤、烧伤、休克、感染等危重患者常见且严重的并发症,发病率和死亡率高。尽管脓毒症治疗已取得很大成就,但其继发并发症仍使脓毒症患者死亡率持续升高。脓毒症心肌病(SCM)是威胁脓毒症患者生命的主要并发症之一,指随原发病加重出现的心肌功能障碍,表现为双心室扩张伴左心室射血分数(LVEF)下降。现有研究显示SCM机制包括心肌线粒体功能障碍、心肌细胞凋亡、钙循环障碍等,治疗包括常规治疗、β1受体阻滞剂治疗和中医药治疗等,本文就此进行综述。

要点

  • 脓毒症心肌病(SCM)表现为双心室扩张伴左心室射血分数(LVEF)下降,是威胁脓毒症患者生命的主要并发症之一。
  • SCM机制包括心肌线粒体功能障碍、心肌细胞凋亡、钙循环障碍。
  • SCM治疗包括常规治疗、β1受体阻滞剂治疗和中医药治疗等。
  • 脓毒症是创伤、烧伤、休克、感染等危重患者常见且严重的并发症,发病率和死亡率高。

适用人群与场景

  • 脓毒症患者,尤其创伤、烧伤、休克、感染等临床危重患者。

诊断标准与关键阈值

  • SCM指随原发病加重出现的心肌功能障碍,表现为双心室扩张伴左心室射血分数(LVEF)下降。

处置流程与药物剂量

  • SCM治疗包括常规治疗、β1受体阻滞剂治疗和中医药治疗等。

研究设计与关键结果

  • 综述指出SCM机制包括心肌线粒体功能障碍、心肌细胞凋亡、钙循环障碍,治疗包括常规治疗、β1受体阻滞剂治疗和中医药治疗等。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis is a life-threatening organ dysfunction caused by dysregulation of the body's response to infection. It is one of the common and serious complications in clinically critical patients with trauma, burn, shock, infection, etc., with high morbidity and mortality. Although the treatment of sepsis has made great achievements in clinical practice, the mortality of patients with sepsis is still increasing due to its secondary complications. Septic cardiomyopathy (SCM) is one of the major complications that threaten septic patient's life. SCM refers to myocardial dysfunction with the aggravation of the primary disease, which is manifested by biventricular dilatation accompanied by a decrease in left ventricular ejection fraction (LVEF). It is one of the major complications that threaten the life of patients with sepsis. The existing research shows that the mechanism of SCM includes myocardial mitochondrial dysfunction, myocardial cell apoptosis, calcium circulation disorder and its treatment including conventional treatment, β1 receptor blocker treatment and traditional Chinese medicine treatment,etc. This paper reviewed the pathogenesis of SCM and its related, in order to provide references for the rational diagnosis and treatment of SCM.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Dilireba T, Yang C, Wang Y, et al. [Research advance of the mechanism and treatment of septic cardiomyopathy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36473575. doi:10.3760/cma.j.cn121430-20210623-00938

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。